BACKGROUND: Hypercholesterolemia is common in perinatally HIV-infected (HIV+) children, but little is known about the clinical course and management in this population. METHODS: We studied HIV+ children in a multisite prospective cohort study (Pediatric AIDS Clinical Trials Group 219C) and considered follow-up for 2 years after development of hypercholesterolemia. We estimated the time and factors associated with resolution of hypercholesterolemia and described changes in antiretroviral regimen and use of lipid-lowering medications. We defined incident hypercholesterolemia as entry total cholesterol (cholesterol) <220 mg/dL and 2 subsequent consecutive cholesterol ≥ 220 mg/dL and defined resolution of hypercholesterolemia as 2 consecutive cholesterol <200 mg/dL after incident hypercholesterolemia. RESULTS: Among 240 incident hypercholesterolemia cases, 81 (34%) had resolution to normal cholesterol within 2 years of follow-up (median follow-up = 1.9 years). The median age of cases was 10.3 years with 54% non-Hispanic black and 53% male. Resolution to normal cholesterol was more likely in children who changed antiretroviral regimen (adjusted hazard ratio = 2.37, 95% confidence interval: 1.45 to 3.88) and who were 13 years and older (aHR = 2.39, 95% confidence interval: 1.33 to 4.27). Types of regimen changes varied greatly, and 15 children began statins. CONCLUSION: The majority of children who develop hypercholesterolemia maintain elevated levels over time, potentially placing them at risk for premature cardiovascular morbidity.
BACKGROUND:Hypercholesterolemia is common in perinatally HIV-infected (HIV+) children, but little is known about the clinical course and management in this population. METHODS: We studied HIV+ children in a multisite prospective cohort study (Pediatric AIDS Clinical Trials Group 219C) and considered follow-up for 2 years after development of hypercholesterolemia. We estimated the time and factors associated with resolution of hypercholesterolemia and described changes in antiretroviral regimen and use of lipid-lowering medications. We defined incident hypercholesterolemia as entry total cholesterol (cholesterol) <220 mg/dL and 2 subsequent consecutive cholesterol ≥ 220 mg/dL and defined resolution of hypercholesterolemia as 2 consecutive cholesterol <200 mg/dL after incident hypercholesterolemia. RESULTS: Among 240 incident hypercholesterolemia cases, 81 (34%) had resolution to normal cholesterol within 2 years of follow-up (median follow-up = 1.9 years). The median age of cases was 10.3 years with 54% non-Hispanic black and 53% male. Resolution to normal cholesterol was more likely in children who changed antiretroviral regimen (adjusted hazard ratio = 2.37, 95% confidence interval: 1.45 to 3.88) and who were 13 years and older (aHR = 2.39, 95% confidence interval: 1.33 to 4.27). Types of regimen changes varied greatly, and 15 children began statins. CONCLUSION: The majority of children who develop hypercholesterolemia maintain elevated levels over time, potentially placing them at risk for premature cardiovascular morbidity.
Authors: K Mulligan; C Grunfeld; V W Tai; H Algren; M Pang; D N Chernoff; J C Lo; M Schambelan Journal: J Acquir Immune Defic Syndr Date: 2000-01-01 Impact factor: 3.731
Authors: Joseph J Eron; Benjamin Young; David A Cooper; Michael Youle; Edwin Dejesus; Jaime Andrade-Villanueva; Cassy Workman; Roberto Zajdenverg; Gerd Fätkenheuer; Daniel S Berger; Princy N Kumar; Anthony J Rodgers; Melissa A Shaughnessy; Monica L Walker; Richard J O Barnard; Michael D Miller; Mark J Dinubile; Bach-Yen Nguyen; Randi Leavitt; Xia Xu; Peter Sklar Journal: Lancet Date: 2010-01-12 Impact factor: 79.321
Authors: A J Flammer; N T T Vo; B Ledergerber; F Hermann; A Gämperli; A Huttner; J Evison; I Baumgartner; M Cavassini; D Hayoz; K Quitzau; M Hersberger; I Sudano; F Ruschitzka; T F Lüscher; G Noll; R Weber Journal: Heart Date: 2008-07-24 Impact factor: 5.994
Authors: M Isabel Gonzalez-Tome; Jose Tomas Ramos Amador; M Jose Mellado Peña; M Luisa Navarro Gomez; Pablo Rojo Conejo; Pablo Martin Fontelos Journal: BMC Infect Dis Date: 2008-10-22 Impact factor: 3.090
Authors: Shirin Heidari; Lynne M Mofenson; Charlotte V Hobbs; Mark F Cotton; Richard Marlink; Elly Katabira Journal: J Acquir Immune Defic Syndr Date: 2012-02-01 Impact factor: 3.731
Authors: J Jao; W Yu; K Patel; T L Miller; B Karalius; M E Geffner; L A DiMeglio; A Mirza; J S Chen; M Silio; E J McFarland; R B Van Dyke; D Jacobson Journal: HIV Med Date: 2017-11-21 Impact factor: 3.180
Authors: Steven E Lipshultz; Tracie L Miller; James D Wilkinson; Gwendolyn B Scott; Gabriel Somarriba; Thomas R Cochran; Stacy D Fisher Journal: J Int AIDS Soc Date: 2013-06-18 Impact factor: 5.396